These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32538726)

  • 1. A Review on Emerging Drug Targets in Treatment of Schizophrenia.
    Ved HS; Doshi GM
    Curr Drug Targets; 2020; 21(15):1593-1605. PubMed ID: 32538726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE; Schaffhauser H; Campbell UC
    Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.
    Wierońska JM; Zorn SH; Doller D; Pilc A
    Pharmacol Ther; 2016 Jan; 157():10-27. PubMed ID: 26549541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
    Foster DJ; Jones CK; Conn PJ
    Discov Med; 2012 Dec; 14(79):413-20. PubMed ID: 23272693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery.
    Cieślik P; Wierońska JM
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.
    Clark SD; Abi-Dargham A
    Biol Psychiatry; 2019 Oct; 86(7):502-511. PubMed ID: 31376930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasticity of Signaling by Spinal Estrogen Receptor α, κ-Opioid Receptor, and Metabotropic Glutamate Receptors over the Rat Reproductive Cycle Regulates Spinal Endomorphin 2 Antinociception: Relevance of Endogenous-Biased Agonism.
    Liu NJ; Murugaiyan V; Storman EM; Schnell SA; Kumar A; Wessendorf MW; Gintzler AR
    J Neurosci; 2017 Nov; 37(46):11181-11191. PubMed ID: 29025923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases.
    Fuenzalida M; Pérez MÁ; Arias HR
    Curr Pharm Des; 2016; 22(14):2004-14. PubMed ID: 26818867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of dynorphin-KOR system and mGluR5 in rat hippocampus.
    Wang X; Wang Y; Zhang C; Liu C; Zhao B; Wei N; Zhang JG; Zhang K
    Brain Res; 2016 Sep; 1646():174-181. PubMed ID: 27262683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cholinergic System: An Emerging Drug Target for Schizophrenia.
    Gibbons A; Dean B
    Curr Pharm Des; 2016; 22(14):2124-33. PubMed ID: 26818859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice.
    Cieślik P; Radulska A; Pelikant-Małecka I; Płoska A; Kalinowski L; Wierońska JM
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous activation of muscarinic and GABA
    Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM
    Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    Terry AV; Callahan PM
    Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotics in the early stage of development.
    Biedermann F; Fleischhacker WW
    Curr Opin Psychiatry; 2009 May; 22(3):326-30. PubMed ID: 19346948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain.
    Terry AV; Gearhart DA; Mahadik SP; Warsi S; Waller JL
    Neuroscience; 2006 Jul; 140(4):1277-87. PubMed ID: 16626873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mGlu
    Yohn SE; Foster DJ; Covey DP; Moehle MS; Galbraith J; Garcia-Barrantes PM; Cho HP; Bubser M; Blobaum AL; Joffe ME; Cheer JF; Jones CK; Lindsley CW; Conn PJ
    Mol Psychiatry; 2020 Nov; 25(11):2786-2799. PubMed ID: 30116027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.